Free Trial
NASDAQ:SGMT

Sagimet Biosciences Q4 2024 Earnings Report

Sagimet Biosciences logo
$3.31 +0.16 (+5.08%)
Closing price 04/28/2025 04:00 PM Eastern
Extended Trading
$3.25 -0.06 (-1.78%)
As of 04:20 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sagimet Biosciences EPS Results

Actual EPS
-$0.50
Consensus EPS
-$0.65
Beat/Miss
Beat by +$0.15
One Year Ago EPS
N/A

Sagimet Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Sagimet Biosciences Announcement Details

Quarter
Q4 2024
Time
Before Market Opens
Conference Call Date
Wednesday, March 12, 2025
Conference Call Time
7:30AM ET

Upcoming Earnings

Sagimet Biosciences' Q1 2025 earnings is scheduled for Wednesday, May 21, 2025, with a conference call scheduled on Thursday, May 15, 2025 at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Sagimet Biosciences Earnings Headlines

Sagimet Biosciences announces presentations at EASL Congress 2025
$2 Trillion Disappears Because of Fed's Secretive New Move
$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being carried out by the Fed that has nothing to do with lowering or raising interest rates... but could soon have an enormous impact on your wealth.
Sagimet Biosciences reports Q4 EPS (50c), consensus (63c)
See More Sagimet Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Sagimet Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Sagimet Biosciences and other key companies, straight to your email.

About Sagimet Biosciences

Sagimet Biosciences (NASDAQ:SGMT), a clinical-stage biopharmaceutical company, develops therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic pathways in the United States. The company's lead drug candidate is Denifanstat, a once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction associated steatohepatitis. It also develops TVB-3567, a FASN inhibitor for the treatment of acne; and other oncology programs. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

View Sagimet Biosciences Profile

More Earnings Resources from MarketBeat